High Dose Influenza Vaccine in Nursing Home - Pilot Study

Insight Therapeutics

Status and phase: Completed; Phase 4

Conditions: Influenza

Treatments: Biological: HD Fluzone Vaccine; Biological: SD Fluzone Vaccine

Study type: Interventional

Funder types: Other

Identifiers

NCT01720277

GRC75-HD Nursing Home Pilot

Details and patient eligibility

About

The purpose of this pilot evaluation is to help determine the feasibility and power needed to prospectively evaluate relative effectiveness of high-dose influenza vaccine in preventing influenza mortality and hospitalization in a nursing home population in the U.S., compared to the standard-dose influenza vaccine.

Full description

Influenza remains the most common preventable respiratory viral infection of older adults. Older adults incur more than 90% of the disease burden, and those residing in nursing homes are the most affected subset given their immune senescence, multi-morbidity, and close living quarters. Each year, the majority of influenza-related hospitalizations occur during the period with the greatest influenza activity.

Influenza vaccination has been associated with reduced hospitalization, strokes, heart attacks and death in non-institutional older adult populations, but the benefit of influenza vaccine for the oldest population has been questioned. The new high-dose influenza vaccine is considerably more immunogenic in older adults, and has recently been approved for use in individuals aged 65 years and older. No clinical data yet confirm whether the improved immunogenicity translates into added clinical benefit, such as further reduction in hospitalization or death. Estimating the benefit of influenza vaccination among older adults in long-term care settings using randomized controlled trials requires extensive effort and is costly. Instead, a pragmatic RCT in a nursing home population has several advantages as a model for comparing therapeutic approaches.

This clinical trial aims to test the feasibility of our protocol for a subsequent larger study. We aim to demonstrate that we can recruit and enroll facilities; randomly assign and coordinate vaccine delivery; collect data; conduct site audits for data validation; create outcomes using multiple data sources; and conduct analyses.

Enrollment: 2,957 patients

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Long-term care facilities in one of the 122 cities that serve as Center for Disease Control and Prevention (CDC) surveillance sites

Exclusion criteria

• Facilities already systematically administering HD vaccine to their residents
• Facilities for whom over half the residents are on Medicare (short-stay)
• Facilities in which over half the residents are on Medicare Part A (SNF)
• Facilities having fewer than 50 long-stay residents
• Hospital-based facilities
• Facilities with more than 20% of the population under age 65
• Facilities with mandated (employment-dependent) seasonal influenza vaccination
• Facilities not submitting MDS data

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

2,957 participants in 2 patient groups

HD Fluzone Vaccine

Experimental group

Description:

NH facilities randomized to receive high dose trivalent influenza vaccine (HD Fluzone) for the residents.

Treatment:

Biological: HD Fluzone Vaccine

SD Fluzone Vaccine

Active Comparator group

Description:

NH facilities randomized to standard dose trivalent influenza vaccine (SD Fluzone) for the residents.

Treatment:

Biological: SD Fluzone Vaccine